Awakn Life Sciences Corp.
AWKNFOTCHealthcare
$0.07
+$0.00(+0.00%)
Market Cap$2708069
P/E Ratio—
52W High$0.1334
52W Low$0.04872
Awakn Life Sciences Corp. (AWKNF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
AWKNF · earnings · updated Jun 9, 2026
Latest Earnings
Q4 FY2024Report Date: Dec 13, 2024EPS Actual
-$0.01
Revenue
$0.00B
Fiscal Period
Q4 FY2024
FY ends December
Report Date
Dec 13, 2024
After Market Close
✓ 3-Quarter EPS Beat Streak
AWKNF reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$-0.11
Rev. $0.17B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$-0.11
Rev. Est.$0.17B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| — Q4 FY2024 | Dec 13, 2024 | — | -$0.01 | — | $0.00B | — | — |
| — Q3 FY2024 | Sep 26, 2024 | — | -$0.01 | — | $0.00B | — | — |
| ▲ Q2 FY2024 | May 28, 2024 | -$0.02 | -$0.01 | +54.4% | $0.00B | — | — |
| ▲ Q2 FY2024 | Apr 25, 2024 | -$0.02 | -$0.02 | +12.7% | $0.00B | — | — |
| ▲ Q4 FY2023 | Oct 31, 2023 | -$0.02 | -$0.02 | +28.7% | $0.00B | — | — |
| ▼ Q3 FY2023 | Jul 31, 2023 | -$0.03 | -$0.05 | -50.4% | $0.00B | — | — |
| ▼ Q2 FY2023 | Apr 30, 2023 | -$0.04 | -$0.05 | -25.0% | $0.00B | $0.00B | -26.1% |
| — Q1 FY2023 | Jan 31, 2023 | — | -$0.07 | — | $0.00B | — | — |
Q4 FY2024
Dec 13, 2024
EPS Actual
-$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q3 FY2024
Sep 26, 2024
EPS Actual
-$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q2 FY2024
May 28, 2024Beat
EPS Actual
-$0.01
EPS Est.
-$0.02
EPS Surpr.
+54.4%
Revenue
$0.00B
Q2 FY2024
Apr 25, 2024Beat
EPS Actual
-$0.02
EPS Est.
-$0.02
EPS Surpr.
+12.7%
Revenue
$0.00B
Q4 FY2023
Oct 31, 2023Beat
EPS Actual
-$0.02
EPS Est.
-$0.02
EPS Surpr.
+28.7%
Revenue
$0.00B
Q3 FY2023
Jul 31, 2023Miss
EPS Actual
-$0.05
EPS Est.
-$0.03
EPS Surpr.
-50.4%
Revenue
$0.00B
Q2 FY2023
Apr 30, 2023Miss
EPS Actual
-$0.05
EPS Est.
-$0.04
EPS Surpr.
-25.0%
Revenue
$0.00B
Q1 FY2023
Jan 31, 2023
EPS Actual
-$0.07
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2023 | $-0.05 | $-0.05 | $-0.05 | 1 |
| Q1 FY2023 | $-0.06 | $-0.06 | $-0.06 | 1 |
| Q4 FY2022 | $-0.08 | $-0.08 | $-0.08 | 1 |
| Q3 FY2022 | $-0.08 | $-0.08 | $-0.08 | 1 |
| Q2 FY2022 | $-0.15 | $-0.15 | $-0.15 | 1 |
| Q1 FY2022 | $-0.14 | $-0.14 | $-0.14 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2023 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2023 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2022 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2022 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2022 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2022 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q4 FY2024 | Dec 13, 2024 | — | $0.08 | $0.07 | -18.44% |
| — Q3 FY2024 | Sep 26, 2024 | — | $0.07 | $0.06 | -7.69% |
| ▲ Q2 FY2024 | May 28, 2024 | +54.4% | $0.14 | $0.13 | -8.93% |
| ▲ Q2 FY2024 | Apr 25, 2024 | +12.7% | $0.14 | $0.14 | -1.72% |
| ▲ Q4 FY2023 | Oct 31, 2023 | +28.7% | $0.19 | $0.17 | -10.90% |
| ▼ Q3 FY2023 | Jul 31, 2023 | -50.4% | $0.19 | $0.18 | -2.66% |
| ▼ Q2 FY2023 | Apr 30, 2023 | -25.0% | $0.27 | $0.27 | +0.00% |
| — Q1 FY2023 | Jan 31, 2023 | — | $0.24 | $0.25 | +6.10% |
Q4 FY2024-18.44%
Report Date
Dec 13, 2024
EPS Beat/Miss
—
Price Before
$0.08
Price After
$0.07
Q3 FY2024-7.69%
Report Date
Sep 26, 2024
EPS Beat/Miss
—
Price Before
$0.07
Price After
$0.06
Q2 FY2024-8.93%
Report Date
May 28, 2024
EPS Beat/Miss
+54.4%
Price Before
$0.14
Price After
$0.13
Q2 FY2024-1.72%
Report Date
Apr 25, 2024
EPS Beat/Miss
+12.7%
Price Before
$0.14
Price After
$0.14
Q4 FY2023-10.90%
Report Date
Oct 31, 2023
EPS Beat/Miss
+28.7%
Price Before
$0.19
Price After
$0.17
Q3 FY2023-2.66%
Report Date
Jul 31, 2023
EPS Beat/Miss
-50.4%
Price Before
$0.19
Price After
$0.18
Q2 FY2023+0.00%
Report Date
Apr 30, 2023
EPS Beat/Miss
-25.0%
Price Before
$0.27
Price After
$0.27
Q1 FY2023+6.10%
Report Date
Jan 31, 2023
EPS Beat/Miss
—
Price Before
$0.24
Price After
$0.25
Avg Beat Reaction-7.18%
Avg Miss Reaction-1.33%
Beat Rate3 / 8 quarters
Largest Move-18.44% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: AWKNF ends December
Awakn Life Sciences Corp. (AWKNF) most recently reported earnings on December 13, 2024 for Q4 FY2024, posting EPS of $-0.01 (in line with the analyst consensus of —). AWKNF has beaten EPS estimates for 3 consecutive quarters. The next AWKNF earnings date is expected around September 1, 2026.
Each quarter, investors track AWKNF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. AWKNF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
AWKNF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
AWKNF earnings · 4 questionsAwakn Life Sciences Corp.'s next earnings report is expected around September 1, 2026. AWKNF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; AWKNF historically reports after market close (AMC).
AWKNF earnings datewhen is AWKNF earningsAWKNF next earnings datewhen does AWKNF report earningsAWKNF earnings calendar
▸ Source: FMP · Awakn Life Sciences Corp. SEC filings · US GAAP · Awakn Life Sciences Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026